Dr. Azab completed his Pharmacy studies, M.Sc. (in Medicinal Chemistry), and Ph.D. (in Pharmaceutical Sciences) at the Hebrew University of Jerusalem, and a post-doctoral training (in Cancer Biology and Immunology) at Dana-Farber Cancer Institute, Harvard University. His first academic position was at Washington University in St. Louis, Department of Radiation Oncology and Department of Biomedical Engineering.
Read More
Dr. Azab completed his Pharmacy studies, M.Sc. (in Medicinal Chemistry), and Ph.D. (in Pharmaceutical Sciences) at the Hebrew University of Jerusalem, and a post-doctoral training (in Cancer Biology and Immunology) at Dana-Farber Cancer Institute, Harvard University. His first academic position was at Washington University in St. Louis, Department of Radiation Oncology and Department of Biomedical Engineering.
The research in Dr. Azab’s laboratory is multidisciplinary (including biomedical engineering, cancer biology and immunology, pharmaceutical sciences, and medicinal chemistry), aiming to translate the laboratory findings into patient care through clinical trials and entrepreneurial approaches. Specifically, it focuses on development of novel cancer therapeutics, mainly through discovery of cancer-specific biomarkers and mechanisms which involve the effect of tumor microenvironment (TME) in drug resistance and metastasis, as well as development of novel solutions for cancer immunotherapy, tissue engineered cancer models ex vivo for drug development and personalized medicine, and an array of drug delivery systems including lipid and polymeric nanoparticles for systemic delivery, and drug eluting biodegradable implants for local therapy, for improved efficacy and reduced toxicity of cancer therapy.
Dr. Azab has published over a 100 research articles, was cited over 7800 times, mentored over 50 trainees, and is the founder of 4 startup biotech companies (Cellatrix LLC, Targeted Therapeutics LLC, OncInsights LLC, and ACE Nanotherapeutics LLC).
Read Less
